CU-CPT9a

Catalog No.S9730 Batch:S973001

Technical Data

Formula	C₁₇H₁₅NO₂
Molecular Weight	265.31	CAS No.	2165340-32-7
Solubility (25°C)*	In vitro	DMSO	53 mg/mL (199.76 mM)
		Ethanol	10 mg/mL (37.69 mM)
		Water	Insoluble
* <1 mg/ml means slightly soluble or insoluble. * Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations. * Room temperature shipping (Stability testing shows this product can be shipped without any cooling measures.)

Preparing Stock Solutions

Biological Activity

Description

CU-CPT9a is a potent and specific antagonist of Toll-like receptor 8 (TLR8) with IC50 of 0.5 nM.

Targets

TLR8 ^[1]
(Cell-free assay)

0.5 nM

In vitro

PBMC treatment with R848 or RNA-40 induces IL-6 production, and this activation is suppressed by CU-CPT9a in a dose-dependent manner. A dose-dependent suppression of IL-6 production by CU-CPT9a is also observed when cells are stimulated with violacein. Previous addition of CU-CPT9a only blocks IL-1β stimulated by R848 and has no effect on violacein-induced IL-1β stimulation.^[2]

Protocol (from reference)

Cell Assay:^{^[2]}	Cell lines Human PBMCs Concentrations 0.02 μmol/L, 0.2 μmol/L, 2 μmol/L, 20 μmol/L Incubation Time 1 h Method Human PBMCs are cultured (50 μL of 6 × 10⁶ live cells/mL) in a 96-well plate. Cells are treated with different concentrations of CU-CPT9a (0.02, 0.2, 2 and 20 μmol/L) or medium as a negative control and are incubated for 1 h at 37 °C, 5% CO2. After this, cells are treated with violacein (30 and 15 μmol/L), R848 (1 μmol/L), LPS (50 ng/mL) or RNA-40 (5 μg/mL). After incubating for 20 h, the culture supernatants are collected and used to measure the concentration of IL-6 or IL-1β by ELISA according to the manufacturer’s instructions.

Cell Assay:^{^[2]}

Cell lines
Human PBMCs
Concentrations
0.02 μmol/L, 0.2 μmol/L, 2 μmol/L, 20 μmol/L
Incubation Time
1 h
Method
Human PBMCs are cultured (50 μL of 6 × 10⁶ live cells/mL) in a 96-well plate. Cells are treated with different concentrations of CU-CPT9a (0.02, 0.2, 2 and 20 μmol/L) or medium as a negative control and are incubated for 1 h at 37 °C, 5% CO2. After this, cells are treated with violacein (30 and 15 μmol/L), R848 (1 μmol/L), LPS (50 ng/mL) or RNA-40 (5 μg/mL). After incubating for 20 h, the culture supernatants are collected and used to measure the concentration of IL-6 or IL-1β by ELISA according to the manufacturer’s instructions.

References

Selleck's CU-CPT9a has been cited by 2 publications

Erythroid-intrinsic activation of TLR8 impairs erythropoiesis in inherited anemia [ Nat Commun, 2024, 15(1):5678]	PubMed: 38971858
IRAK1 inhibition blocks the HIV-1 RNA mediated pro-inflammatory cytokine response from microglia [ J Gen Virol, 2023, 104(5)001858]	PubMed: 37256770

RETURN POLICY
Selleck Chemical’s Unconditional Return Policy ensures a smooth online shopping experience for our customers. If you are in any way unsatisfied with your purchase, you may return any item(s) within 7 days of receiving it. In the event of product quality issues, either protocol related or product related problems, you may return any item(s) within 365 days from the original purchase date. Please follow the instructions below when returning products.

SHIPPING AND STORAGE
Selleck products are transported at room temperature. If you receive the product at room temperature, please rest assured, the Selleck Quality Inspection Department has conducted experiments to verify that the normal temperature placement of one month will not affect the biological activity of powder products. After collecting, please store the product according to the requirements described in the datasheet. Most Selleck products are stable under the recommended conditions.

NOT FOR HUMAN, VETERINARY DIAGNOSTIC OR THERAPEUTIC USE.